Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Sanofi faces AGM row over cost of firing and hiring CEOs

Published 30/04/2015, 20:29
© Reuters. A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris
BAYGN
-
SASY
-

By Andrew Callus

PARIS (Reuters) - Drugs group Sanofi (PA:SASY), which sacked its chief executive last year and appointed a new one in February, has appealed for shareholder loyalty as it seeks to head off a potential rebellion over millions of euros in payments to both men.

Investor advisory group ISS has recommended a vote against two resolutions that would approve those payments at the French company's annual general meeting (AGM) on Monday.

In a letter to shareholders on its website, the company said: "If Sanofi is taking the initiative today of contacting you directly, it is because these recommendations do not reflect a simple difference of opinion; they reflect a real error in analysis by ISS."

One of the ISS objections relates to approval of a joining bonus, a giant pension pot and other terms for new CEO Olivier Brandicourt. The second covers non-compete and confidentiality severance payments for his predecessor, Chris Viehbacher.

The former CEO won a total 4.44 million euros ($4.95 million). In exchange, he agreed not to work for a competitor until June, not to recruit Sanofi employees for 18 months and to adhere to a two-year confidentiality agreement.

Brandicourt, meanwhile, could earn up to 4.2 million euros a year and pocket an extra 4 million euros as a one-off golden hello. He was also awarded a pension pot equivalent to 10 years' service.

"SHAREHOLDER-UNFRIENDLY"

Another advisory group, Proxinvest, which backs ISS's position, has estimated the value of the pension pot at 9 million euros and ISS said the pension award "goes against market standards in France".

ISS also objected to the way the company was "bundling" a vote on the pension with other parts of Brandicourt's employment terms into one resolution on an auditors' special report, describing the action as "poor and shareholder-unfriendly practice".

Sanofi's letter said that Brandicourt's recruitment conditions "need to be considered as a whole". He was recruited from Bayer Healthcare, part of German group Bayer (DE:BAYGn), and elements of the deal are to compensate him for a loss of benefits there.

His package has already drawn criticism from France's Socialist government, which is sensitive about executive pay in a period of high unemployment. Agriculture Minister Stephane Le Foll called it "incomprehensible".

Defending its payment to Viehbacher, Sanofi argued that the payoff had avoided a protracted legal dispute and was substantially less than the outgoing boss had sought. It also said it had obtained "valuable undertakings" from him.

ISS's hackles have also been raised by the fact that the Viehbacher resolution -- unlike the vote on Brandicourt's remuneration -- is merely advisory and the vote non-binding.

The investor group acknowledged Sanofi's arguments for the settlement itself but said there should still be a proper vote because the terms were not those in Viehbacher's contract.

© Reuters. A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.